Announcement on Subsidiary Companies Obtaining Drug Registration Approval
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Sharp Group No.: Pro 2019-007
Bond Abbreviation: 13 Spike 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Registration Approval
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Registration Approval Document" (Approval No.: 2019S00296) of olopatadine hydrochloride eye drops approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of
1. Drugs
Drug Name: Olopatadine Hydrochloride Eye Drops
Dosage Form: Ophthalmic Preparation
Specification: 0.1 (5ml:5mg, based on C 21 H 23 NO 3 )
Application Items: Domestic Drug Registration
Registration Classification: Chemical Drug Class 4
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Acceptance Number: CYHS1600042 Zhejiang
batch number: 2019S00296
drug standard number: YBH00792019
drug validity period: 36 months
drug approval number: national drug H20193095
drug approval number validity period: until April 02, 2024
approval conclusion: according to the "the People's Republic of China Drug Administration Law" and relevant regulations, after examination, this product meets the relevant requirements of drug registration, approves the registration, and issues the drug approval number.
Other relevant conditions of 2. drug
This drug is used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1- receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments.
Olopatadine Hydrochloride Eye Drops has been included in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) and classified as Class B; it is not included in the National Essential Drugs List (2018 Edition). At present, Novartis Europharm Limited, towering pharmaceutical (China) co., ltd., Jiangsu hanchen pharmaceutical co., ltd., Jiangxi kelun pharmaceutical co., ltd., Guangdong hongying technology co., ltd., Qilu pharmaceutical co., ltd. and Shenyang xingqi ophthalmic co., ltd. olopatadine hydrochloride eye drops have been approved for listing in China. After querying the IMS database, global sales of olopatadine hydrochloride eye drops in 2018 were approximately US $0.37 billion and China sales were approximately US $10.232 million.
Up to now, the research and development investment of spiking pharmaceutical olopatadine hydrochloride eye drops project is about 660 yuan. The impact of
3. on the company
Jianfeng Pharmaceutical already has a corresponding production line. This time, it has obtained the Drug Registration Approval Document of olopatadine hydrochloride eye drops, which indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug. It will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business.
4. Risk Warning
Company attaches great importance to the quality and safety of drug research and development, manufacturing and sales. However, due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the early stage of drug research and development, approval to production has a long cycle, large investment and many links, moreover, the production and sales of drugs after obtaining approval are also vulnerable to national policies, market environment and other factors. Please the majority of investors cautious decision-making, pay attention to prevent investment risk.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 17, 2019
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31